Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Forest's Celexa Adds Warning On Dose-Dependent QT Prolongation

This article was originally published in The Pink Sheet Daily

Executive Summary

The labeling revision, which reflects the results of a thorough QT study, makes Celexa the first drug in the SSRI/SNRI class of antidepressants to include a general warning about QT interval effects.
Advertisement

Related Content

Amylin's Once-Weekly Bydureon Clears Major Cardiac Safety Hurdle
AstraZeneca's Vandetanib Approval Includes REMS With Distribution Restrictions
AstraZeneca's Vandetanib Approval Includes REMS With Distribution Restrictions
Propoxyphene Marketing Halted By FDAAA-Required QT Safety Study

Topics

Advertisement
UsernamePublicRestriction

Register

PS072686

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel